Introduction {#s1}
============

Leukemia is a malignant clonal disease of hematopoietic stem cells ([@B16]). It is estimated that this disease will see more than 0.4 million new cases and 0.3 million related deaths worldwide, according to the GLOBOCAN 2018 ([@B6]). And new leukemia cases account for 31% of new patients of childhood malignancies ([@B50]). Most children with leukemia show rapid onset ([@B33]). Due to the complexity in leukemia typing and prognosis, there is no one-size-fits-all treatment for the disease ([@B39]; [@B24]). At present, main treatment methods for the disease contain the following types: chemotherapy ([@B43]), radiation therapy ([@B44]), targeted therapy ([@B35]), immunotherapy ([@B1]), stem cell transplantation ([@B9]), and the like. After reasonable and comprehensive treatment, the prognosis of leukemia has been greatly improved ([@B31]). A considerable number of patients can be cured or reach long-term stability ([@B38]; [@B25]).

Immunotherapy, a new treatment for cancer, can help the immune system fight cancer ([@B30]). Over the past few decades, immunotherapy has developed targeting cancer at a striking rate ([@B13]). There are many immunotherapies for leukemia, such as chimeric antigen receptor (CAR) T-cell therapy, bispecific T-cell engager (BiTE) therapy, and antibody-drug conjugates (ADCs) ([@B2]; [@B20]; [@B28]). Chimeric antigen receptor T-cell technology is the most influential immunotherapy for childhood leukemia in the last decade ([@B15]). This measure uses autologous T cells to attack malignant cells ([@B49]). Studies have shown that CAR T cells are effective in inducing remission among leukemia patients and thus provide valuable opportunities for subsequent transplantation, finally achieving durable remission ([@B36]). Evidence also has shown that CAR--T-cell therapy can achieve fine effects among patients with recurrent B-cell malignancies or those facing relapse after cord blood transplant, with fewer complications ([@B12]). Bispecific T-cell engager therapy is also a new advance in immunotherapy for childhood leukemia. Preclinical studies have shown that BiTE can realize antileukemia function by targeting T cells and CD33^+^ monocyte myelogenous suppressor cells, recruiting and expanding autologous T cells and inducing acute myeloid leukemia -blasts lysis ([@B23]; [@B19]). Antibody-drug conjugate therapy, another immunotherapy, has been widely concerned. In this approach, cytotoxic molecules could bind to antibodies, and then the antibodies specifically bind to specific tumor antigens, and the cytotoxic molecules would be endocytosed into cells, thereby killing tumor cell from inside ([@B13]). An *in vitro* experiment showed that ADCs could improve the antiproliferation and cytotoxicity of human acute lymphoblastic leukemia cell lines ([@B17]). In the mouse model of leukemia, ADC treatment could significantly improve survival rate without overt toxicity or adverse effects ([@B32]). As an effective antileukemia immunotherapy, ADC has been assessed for its safety and efficacy in leukemia patients ([@B26]).

Immunotherapy is important in treating childhood leukemia, but there is no bibliometric analysis on researches in this field. The purpose of this study was to use bibliometric methods to analyze the top 100 highly cited articles on immunotherapy for childhood leukemia, hoping to have a better understanding of current situation and trend of those researches through analyzing their main characteristics.

Materials and Methods {#s2}
=====================

Data Sources {#s2_1}
------------

Literature on immunotherapy for childhood leukemia was retrieved from Institute for Scientific Information (ISI) website of the Science Core Collection Database of Henan University from the beginning of the database to April 30, 2019 (updated to June 15, 2019). *Childhood*, *pediatric*, *leukemia*, and *immunotherapy* were used as search terms. Retrieved documents were arranged in descending order according to the number of citations, and the top 100 most cited articles were finally obtained.

Data Extraction {#s2_2}
---------------

The top 100 most frequently cited articles were selected, and the following information was extracted from them: the number of citations, the names of the authors, authors' affiliations, country, publication year, article title, article type, journal, Web of Science categories, quartile in category, and impact factor of the journal (2017 edition of Journal Citation Reports).

Two independent researchers evaluated each identified article to identify articles involving immunotherapy for childhood leukemia, regardless of article type. If there were different opinions, a third reviewer would be consulted, and consensus was thus achieved through discussion.

Statistical Analysis {#s2_3}
--------------------

Microsoft Excel 2013 software was used for descriptive statistical analyses, including those on publication year, author, author affiliation, country, journal, and citation number. VOSviewer 1.6.8 ([@B47]) was used to draw figures for keyword co-occurrence network and coauthored network, so as to implement network visualization analysis. In network visualization, each circle and label represented a keyword or researcher, and the size of circles represented the frequency of occurrence. The larger the circle was, more frequently the circle-represented body appeared. Circles adopting different colors in graph represented different clusters. Lines between two circles indicated that two keywords or researchers appeared together. The thicker the lines were, more frequently they appeared together. More relevant two keywords or researchers were, closer two circles located. The minimum number of co-occurrences was adjusted according to graphic results.

Results {#s3}
=======

Characteristics of Included Studies {#s3_1}
-----------------------------------

A total of 360 articles were retrieved from the Web of Science Core Collection Database to introduce immunotherapy for childhood leukemia. Articles are listed in descending order according to the cited frequency; the top 100 articles with the highest cited frequency are selected. All of the top 100 highly cited articles were published between 2000 and 2018, about two to nine articles each year. Of the articles, 99 were published in journals and 1 in a book. These articles were in 19 categories, including hematology, oncology, and immunology. The 100 articles were published by researchers from 23 countries, most from the United States, Germany, Italy, and Japan ([**Figure 1**](#f1){ref-type="fig"}). The 100 articles were published in 52 publications, 7 of which were not included in the 2017 edition of Journal Citation Reports. The quartile in category was distributed in Q1--Q4; impact factors of the journals ranged from 0.698 to 32.621, and basic information of the journals is shown in [**Table 1**](#T1){ref-type="table"}. The average and median number of citations, range of citation number, and interquartile range of the 100 articles were 53.2, 35.5, 17 to 471, and 35.25, respectively. The articles contained 67 original articles, 23 reviews, 6 conference abstracts, 2 letters, 1 editorial material, and 1 book chapter. The information of the top 100 highly cited articles is listed in [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}.

![Countries from which the 100 most highly cited articles originated and the number of our collected articles from each of those countries.](fphar-10-01100-g001){#f1}

###### 

Journals publishing the top 100 most highly cited articles^\#^.

  Journal                                         No. of articles   Quartile in category   Impact factor   Citation count   Country
  ----------------------------------------------- ----------------- ---------------------- --------------- ---------------- ----------------------
  *Leukemia*                                      11                Q1                     10.023          487              England
  *Blood*                                         10                Q1                     15.132          495              USA
  *Bone Marrow Transplantation*                   6                 Q1                     4.497           257              England
  *Clinical Cancer Research*                      6                 Q1                     10.199          364              USA
  *British Journal of Haematology*                4                 Q1                     5.128           134              USA
  *Biology of Blood And Marrow Transplantation*   3                 Q1                     4.484           97               USA
  *Journal of Clinical Oncology*                  3                 Q1                     26.36           570              USA
  *Klinische Padiatrie*                           3                 Q4                     0.698           126              Germany
  *Blood Cells Molecules and Diseases*            2                 Q4                     1.836           175              USA
  *Cancer Genetics and Cytogenetics*              2                 ---                    ---             134              USA
  *Cancer Research*                               2                 Q1                     9.13            74               USA
  *Haematologica---The Hematology Journal*        2                 ---                    ---             67               Italy
  *International Journal of Hematology*           2                 Q3                     1.942           170              USA
  *Journal of Immunology*                         2                 Q2                     4.539           54               USA
  *Medical and Pediatric Oncology*                2                 ---                    ---             231              USA
  *Pediatric Blood & Cancer*                      2                 Q1                     2.646           74               USA
  *PLoS One*                                      2                 Q1                     2.766           74               USA
  *Therapeutic Advances in Hematology*            2                 ---                    ---             81               England
  *Angewandte Chemie---International Edition*     1                 Q1                     12.102          34               Germany
  *Annals of Oncology*                            1                 Q1                     13.93           28               England
  *Annual Review of Medicine*                     1                 Q1                     14.97           197              USA
  *Arthritis and Rheumatism*                      1                 ---                    ---             151              USA
  *Biomarkers*                                    1                 Q3                     1.976           40               England
  *Cancer Cell*                                   1                 Q1                     22.844          30               USA
  *Cancer Discovery*                              1                 Q1                     24.373          251              USA
  *Cancer Immunology Immunotherapy*               1                 Q2                     4.225           21               USA
  *Cancer Journal*                                1                 Q2                     3.519           17               USA
  *Cancer Journal from Scientific American*       1                 ---                    ---             18               USA
  *Clinical Immunology*                           1                 Q2                     3.557           20               USA
  *Current Medicinal Chemistry*                   1                 Q2                     3.469           19               United Arab Emirates
  *Current Opinion in Hematology*                 1                 Q2                     2.821           19               USA
  *Current Opinion in Immunology*                 1                 Q1                     7.932           89               England
  *Cytotherapy*                                   1                 Q1                     3.993           19               England
  *Discovery Medicine*                            1                 Q3                     2.398           24               USA
  *Drug Discovery Today*                          1                 Q1                     6.848           25               England
  *Expert Review Of Hematology*                   1                 Q3                     1.937           26               England
  *Frontiers in Immunology*                       1                 Q1                     5.511           20               Switzerland
  *Frontiers in Pediatrics*                       1                 Q2                     2.335           27               Switzerland
  *Haematologica*                                 1                 Q1                     9.09            20               Italy
  *Immunological Reviews*                         1                 Q1                     9.217           36               USA
  *Immunology Letters*                            1                 Q3                     2.436           51               Netherlands
  *International Journal of Cancer*               1                 Q1                     7.36            26               USA
  *Journal of Allergy and Clinical Immunology*    1                 Q1                     13.258          80               USA
  *Journal of Oncology Pharmacy Practice*         1                 Q3                     1.908           17               England
  *Leukemia Research*                             1                 Q3                     2.319           19               England
  *Molecular Immunology*                          1                 Q2                     3.188           20               England
  *Nature Medicine*                               1                 Q1                     32.621          123              USA
  *Nature Reviews Clinical Oncology*              1                 Q1                     24.653          52               USA
  *Oncologist*                                    1                 Q1                     5.306           19               USA
  *Oncotarget*                                    1                 ---                    ---             31               USA
  *Pediatric Hematology and Oncology*             1                 Q3                     1.154           23               USA
  *Science Translational Medicine*                1                 Q1                     16.71           64               USA

^\#^Data from the 2017 edition of Journal Citation Reports.

The Top 10 Authors {#s3_2}
------------------

Among the 100 articles, the researchers who published most articles were T. Klingebiel from Goethe University Frankfurt, Germany, reaching a total of 12 articles, while the second and third authors came from the same university. Of the top 10 authors, nine were from Germany, four from the United States, three from Japan, and one from Italy ([**Table 2**](#T2){ref-type="table"}).

###### 

Top 10 authors most frequently appearing in the articles.

  Rank   Author            Number of articles   Affiliation                             Country
  ------ ----------------- -------------------- --------------------------------------- ---------
  1      Klingebiel T      12                   Goethe University Frankfurt             Germany
  2      Bader P           10                   Goethe University Frankfurt             Germany
  3      Lang P            8                    Eberhard Karls University of Tubingen   Germany
  4a     Gruhn B           6                    Friedrich Schiller University of Jena   Germany
  4b     Grupp Sa          6                    University of Pennsylvania              USA
  4c     Handgretinger R   6                    Eberhard Karls University of Tubingen   Germany
  4d     Niethammer D      6                    Osaka University                        Japan
  4e     Sugiyama H        6                    Osaka University                        Japan
  9      Kreyenberg H      5                    Goethe University Frankfurt             Germany
  10a    Barrett Dm        4                    University of Pennsylvania              USA
  10b    Brown P           4                    Johns Hopkins University                USA
  10c    Dilloo D          4                    Heinrich Heine University Dusseldorf    Germany
  10d    Kremens B         4                    University of Duisburg Essen            Germany
  10e    Locatelli F       4                    University of Pavia                     Italy
  10f    Mackall Cl        4                    Stanford University                     USA
  10g    Oka Y             4                    Osaka University                        Japan
  10h    Zintl F           4                    Friedrich Schiller University of Jena   Germany

The Top 10 Institutions {#s3_3}
-----------------------

Like Eberhard Karls University of Tubingen and National Institutes of Health, the University of Pennsylvania, produced 10% of the top 100 articles, followed by the Goethe University Frankfurt (8%), Johns Hopkins University (8%), and National Cancer Institute (8%) ([**Table 3**](#T3){ref-type="table"}).

###### 

Institutions contributing to the 100 most highly cited articles.

  Institution name                        Country   Number of articles
  --------------------------------------- --------- --------------------
  Eberhard Karls University of Tubingen   Germany   10
  National Institutes of Health           USA       10
  University of Pennsylvania              USA       10
  Goethe University Frankfurt             Germany   8
  Johns Hopkins University                USA       8
  NIH National Cancer Institute           USA       8
  Children's Hospital of Philadelphia     USA       7
  Johns Hopkins Medicine                  USA       7
  St. Jude Children's Research Hospital   USA       7
  Osaka University                        Japan     6

The Top 10 Articles {#s3_4}
-------------------

The top 10 highly cited articles contained four original articles, five reviews, and one book chapter ([**Table 4**](#T4){ref-type="table"}). They were from the United States, Italy, Germany, Japan, and Australia. Of the 10 articles, 6 were published in journals, which ranked Q1 in the 2017 edition of Journal Citation Reports, and 1 in that ranking Q3, while journals publishing the other 3 were not included in the 2017 edition of Journal Citation Reports. The categories of these journals involved blood, tumors, pediatrics, and the like. The top 10 articles covered the updating of treatments for childhood leukemia ([@B41]; [@B37]; [@B29]; [@B3]), different mechanisms of immunotherapy ([@B45]; [@B14]), WT1 targeted therapy ([@B46]; [@B42]), a case series report ([@B11]), and a clinical study ([@B10]).

###### 

Top 10 most highly cited articles^\$^.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author        Title                                                                                                                                                                                          Year   Journal                                 Quartile in category   Impact factor   Citation count   Article type   Country
  ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ --------------------------------------- ---------------------- --------------- ---------------- -------------- -------------------
  Pui CH        Biology, risk stratification, and therapy of pediatric acute leukemias: an update                                                                                                              2011   *Journal of Clinical Oncology*          Q1                     26.36           471              Review         USA

  Sotillo E     Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 Immunotherapy                                                                                 2015   *Cancer Discovery*                      Q1                     24.373          251              Article        USA

  Barrett DM    Chimeric antigen receptor therapy for cancer                                                                                                                                                   2014   *Annual Review of Medicine*             Q1                     14.97           197              Book Chapter   USA

  Diak P        Tumor necrosis factor alpha blockers and malignancy in children forty-eight cases reported to the Food and Drug Administration                                                                 2010   *Arthritis and Rheumatism*              ---                    ---             151              Article        USA

  Fry TJ        CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy                                                                              2018   *Nature Medicine*                       Q1                     32.621          123              Article        USA

  Rodriguez-\   Treatment of Ewing sarcoma family of tumors: current status and outlook for the future                                                                                                         2003   *Medical and Pediatric Oncology*        ---                    ---             129              Review         USA
  Galindo C                                                                                                                                                                                                                                                                                                                          

  Locatelli F   How I treat relapsed childhood acute lymphoblastic leukemia                                                                                                                                    2012   *Blood*                                 Q1                     15.132          112              Review         Italy and Germany

  Sugiyama H    Wilms' tumor gene WT1: its oncogenic function and clinical application                                                                                                                         2001   *International Journal of Hematology*   Q3                     1.942           108              Review         Japan

  Rosenfeld C   WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies                                                              2003   *Leukemia*                              Q1                     10.023          103              Review         USA and Austria

  Dagher R      Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study   2002   *Medical and Pediatric Oncology*        ---                    ---             102              Article        USA
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\$^Data from the 2017 edition of Journal Citation Reports.

Keyword Co-Occurrence Network Visualization {#s3_5}
-------------------------------------------

VOSviewer software was used to draw a figure for keyword co-occurrence network, setting the minimum number of occurrences at 3. As shown in [**Figure 2**](#f2){ref-type="fig"}, circles representing keywords such as *acute lymphoblastic-leukemia*, *bone-marrow-transplantation*, *acute myeloid-leukemia*, *versus-host-disease*, and *stem cell transplantation* are larger than others, indicating that these keywords appeared more frequently. Blinatumomab, a BiTE drug, has been extensively studied.

![Keyword co-occurrence network visualization of the 100 most highly cited articles.](fphar-10-01100-g002){#f2}

Researcher Coauthored Network Visualization {#s3_6}
-------------------------------------------

VOSviewer software was used to analyze coauthorship network of authors, with the minimum number of coauthors at 2, and figure for coauthorship network was drawn ([**Figure 3**](#f3){ref-type="fig"}). Accordingly, circles representing T. Klingebiel, P. Bader, and P. Lang are larger than others, and connection lines between them were denser and thicker, indicating that they contributed to more collaborating articles and had closer relation.

![Author coauthorship network visualization of the 100 most highly cited articles.](fphar-10-01100-g003){#f3}

Discussion {#s4}
==========

In this study, we identified and analyzed the top 100 highly cited articles in the field of immunotherapy for childhood leukemia. Through bibliometric analysis, the status and characteristics of publications in this field were explored, including publication journals, research institutions, authors, and other information. The trends of the most frequently cited articles in this field have been clarified, which provided ideas and directions for researchers.

According to publication years of the top 100 highly cited articles, every year could see two to nine articles highly cited, and only one-fourth of those articles were published in the past 5 years. Perhaps because immunotherapy is an emerging approach, a large amount of preclinical and clinical researches are still in progress. Among the top 100 articles, most were from European and American countries, few from Asia. Reason for such a phenomenon possibly is that leukemia has higher incidence in Europe and the United States. According to statistics, the risk of leukemia is 10 to 20 times higher in Europe and the United States than in Asia ([@B51]). Therefore, many research institutions in Europe and the United States have been exploring in this field. According to the number of citations, the most frequently cited articles in the top 100 ones were cited 471 times. Compared with other features ([@B27]; [@B48]), such figure was not large, probably because research in this field is still in the initial stage, and our research topic involved only the blood system and immunotherapy. However, considering physical, psychological, and financial burden from leukemia on the patients ([@B4]) and enormous potential of immunotherapy in treating this disease, researches in this area are important.

A total of 52 journals were involved in this study. The journals were arranged in descending order according to the number of the top 100 highly cited articles they published. The journals were divided into three groups, each with the same number of the articles, and then the number of journals in the three groups was 4, 14, and 34, respectively, approximate to 1:3^1^:3^2^. The distribution of these publications was consistent with Bradford's Law ([@B5]). Of the top 100 highly cited articles, 66% were published in Q1 (2017 edition of the journal citation report), 9% in Q2 and Q3, separately, and 5% in Q4. Most of them were published in journals possessing high impact factor, while these journals are often subscribed by more researchers, and high-quality research results face more opportunities to be cited ([@B7]).

According to the results of keyword co-occurrence, the top 100 highly cited articles covered various aspects of immunotherapy for childhood leukemia, such as leukemia type, immunotherapy type, immunotherapy mechanism ([@B13]), immunotherapy experiments *in vitro*, animal experiments *in vitro* ([@B32]; [@B17]), preclinical studies, stem cell transplantation, changes in survival time after immunotherapy, and leukemia recurrence. According to the figure for keywords co-occurrence network, we can intuitively observe links between keywords and analyze hot topics of the researches. In recent years, a variety of immunotherapies have been approved for clinical leukemia treatment ([@B21]; [@B22]; [@B34]; [@B18]). Growing preclinical studies have also been used to explore new immunotherapies for different types of leukemia.

From the figure for coauthorship network, coauthorship between authors and comparisons on the number of published articles can be visually observed. After multiple times of drawing network figure, the minimum times for author appearing was set at 2. Even so, most researchers were not presented in network diagram because they did not meet the conditions. Researchers in this field are scattered, and only few of them have published more articles. Researchers such as T. Klingebiel, P. Bader, P. Lang, and B. Gruhn from Germany were in close contact with other researchers in this field and have published more articles.

This study still had some limitations. On the one hand, some of the influential articles may be omitted. We only searched the ISI Web of Science core collection database, and articles in other sources such as PubMed and Scopus might be missed, so our final results may be affected by such operation ([@B40]). On the other hand, the number of citations is only an index to evaluate academic influence of articles. Higher impact factors of journals, greater academic influence of authors in this field, Open Access publishing, higher visibility of institutions, and long publication time of literature may all have positive impact on the number of citations for articles ([@B8]; [@B52]). Besides, the quality of the top 100 articles was not assessed, so the quality of the documents may be different. This may affect the interpretation of the results.

Conclusions {#s5}
===========

In this study, we analyzed the top 100 highly cited articles on immunotherapy for childhood leukemia *via* bibliometrics. Most of the articles were published after the year 2000 on top journals in the field of oncology and hematology. Adoptive immunotherapy and stem cell transplantation are the main topics in these articles, which contributed to the development and optimization of immunotherapy. The United States and European countries such as Germany and Italy were major original countries in this research field. Professor T. Klingebiel from Goethe University Frankfurt represented a leader in the field of immunotherapy for childhood leukemia. This report provided insights into the features and research hotspots of highly cited articles on immunotherapy for childhood leukemia.
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